ArticleOncoTargets and therapy2017
Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Clinicoradiologic features and evolutionary characteristics of pulmonary focal mucinous adenocarcinomas across different density patterns: a retrospective multi-center study.Quantitative imaging in medicine and surgery · 2026Article
- Bilateral pulmonary cavitary mucinous adenocarcinoma in an immunocompetent patient: a case report and literature review.BMC pulmonary medicine · 2025Review
- Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.The oncologist · 2025Review
- [Advances on Molecular Mechanism and Clinical Treatment in Invasive Mucinous Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.The clinical respiratory journal · 2024Article
- [Construction of a Prognostic Prediction Model of Patients with Pathologic N0 in Resected Invasive Mucinous Adenocarcinoma of the Lung].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Mixed invasive mucinous and non-mucinous adenocarcinoma of the lung with hematogenous metastases to multiple organs.Respiratory medicine case reports · 2024Article
- Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).Therapeutic advances in medical oncology · 2024Article
- Clinicopathologic Features and Survival Outcomes of Primary Lung Mucinous Adenocarcinoma Based on Different Radiologic Subtypes.Annals of surgical oncology · 2024Article
- Invasive Mucinous Adenocarcinoma with Acute Respiratory Distress Syndrome Diagnosed by Autopsy Findings.Internal medicine (Tokyo, Japan) · 2023Article
- Surgical resection of a large invasive mucinous adenocarcinoma: A case report.Clinical case reports · 2023Article
- Invasive mucinous adenocarcinoma of the lung: clinicopathological features,Annals of nuclear medicine · 2023Article
- Immunostimulatory and anti-inflammatory impact ofFrontiers in immunology · 2023Article
- Recurrence dynamics after curative surgery in patients with invasive mucinous adenocarcinoma of the lung.Insights into imaging · 2022Article
- Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma.Interactive cardiovascular and thoracic surgery · 2022Article
- CT Features of Stage IA Invasive Mucinous Adenocarcinoma of the Lung and Establishment of a Prediction Model.International journal of general medicine · 2022Article
- Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics.Insights into imaging · 2021Article
- Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe performed an analysis to clarify differences in clinicopathological and molecular features of lung invasive mucinous adenocarcinoma (IMA) based on computed tomography (CT) findings and their impact on prognosis. PATIENTS AND
methodsOn the basis of CT findings, we divided lung IMA into three subtypes: solid, bubbling, and pneumonic. We then investigated differences in clinicopathological characteristics, prognosis, and the expressions of well-identified biomarkers, including cyclooxygenase-2 (Cox-2), excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), class III beta-tubulin, thymidylate synthase (TS), secreted protein acidic and rich in cysteine (SPARC), programmed cell death-1 ligand-1 (PD-L1), and
resultsA total of 29 patients with resected lung IMA were analyzed. Compared with the solid or bubbling type, the pneumonic type had a higher proportion of symptoms, a larger tumor size, a higher pathological stage, and a significantly worse prognosis. The immunohistochemical findings tended to show high expression of RRM1, class III beta-tubulin, and Cox-2 in the tumor and of SPARC in the stroma, but not of ERCC1, TS, and PD-L1 in the tumor. None of the biomarkers with high expression levels in the tumor were prognostic biomarkers, but the expression of SPARC in the stroma was correlated with a poor outcome.
conclusionClinical and pathological features, in conjunction with molecular data, indicate that IMA should be divided into different subgroups. In our results, the pneumonic type was correlated with a significantly worse outcome. Further studies should be performed to confirm our conclusion and to explore its molecular implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.